Question Bank › Doing it our way now

Doing it our way now

Doing it our way now: the approach this company pioneered is becoming the market's way

Calls Tested
500
Answered YES
6
Hit Rate
1.2%
rare by design

Pacira BioSciences, Inc. (PCRX) — this company's answers

NO on the Q4 2017 call 2018-02-28 C
The model's full reasoning — Q4 2017 call → NOWe need answer question. Need use only transcript. Need determine if management describes company's way/approach/product being adopted/copied/moved toward by others, validating. Need YES/NO. Transcript is Pacira earnings call about EXPAREL opioid alternative. Need find if management says others are following their way, product becoming standard, being copied. They discuss partnerships, FDA guidance generic, payers recognizing, J&J collaboration, institutions adopting opioid-sparing protocols. Need be careful: The essence is market validating by imitation what company built first, while still ahead. Look for explicit descriptions of others adopting company's approach. They mention "opioid-free alternative", "opioid-sparing solutions", partners share commitment. But is that "others following the company's lead"? They have partnerships with hospitals to develop protocols. They mention "commercial payers already recognize economic advantage of reimbursing EXPAREL separately under C9290. They are supporting enhanced recovery after surgery protocols with EXPAREL and shifting many inpatient procedures to outpatient." That's adoption, not imitation? They are using company's product. But question about company's way of doing things being adopted by others in market. Could be "others are now following the company's lead" e.g., hospitals adopting opioid-sparing protocols? But management describes partners and collaborators, not necessarily competitors copying. Need identify if management explicitly states that its approach is now becoming common practice or others trying to replicate. The transcript: Dave: "The only single administration long acting local analgesic... uniquely positioned...". "In addition to our own dedicated internal initiatives, we have forged several meaningful partnerships that are helping us get the message out". Partners: J&J, Cancer Treatment Centers, etc. "These partners share our commitment to reducing the role of the operating room as gateway." Not "others following". Also FDA guidance for generic EXPAREL: "This guidance underscores tremendously high technical and financial hurdles facing any potential generic competitor... FDA guidance also highlights EXPAREL's complex multivesicular honeycomb structure... leaves us confident in long-term exclusivity in unlikely event of future generic competition." This is about barriers, not adoption.

← Back to the full PCRX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the WAY THIS COMPANY DOES THINGS — an approach, product design, technology, method, business model, or way of serving customers that the company pioneered, built, or is identified with — is NOW BEING ADOPTED, COPIED, OR MOVED TOWARD BY OTHERS IN ITS MARKET, so that the company's own way of doing things is becoming the market's way? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon: others are now following the company's lead, and management treats that following as present-day validation of what the company built. Any genuine expression of this counts, and the form varies widely across industries. For example — competitors or new entrants launching products, services, pricing models, or strategies that follow the company's; management noting that an approach the company was once doubted, dismissed, or criticized for is now becoming common practice; customers, partners, or suppliers telling the company that others are trying to replicate what it does; industry standards, specifications, architectures, formats, or norms converging on the company's design or method; suppliers, manufacturers, or platforms retooling themselves around the company's requirements; new entrants explicitly modeling themselves on the company; or management describing that the conversation in its market has shifted from whether the company's way works to how others can catch up. Two things should come through in management's own voice. First, the following must be REAL AND ALREADY OBSERVABLE — described as behavior happening now, grounded in something concrete (who is following, or what specifically is being adopted), not a bare claim that the company is "the leader," "the standard," or "best in class," and not a prediction that the world will someday come around. Second, management must treat the convergence as CONFIRMING the company's position — its lead, head start, or next move described as intact or advancing — not as a threat that is eroding its results or forcing it onto the defensive. The essence is ONE phenomenon: the market is validating, by imitation, what this company built first — and the company is describing it while still ahead. The industry, the thing being followed, and the form of the following may vary widely. Answer NO if management merely claims the company is different, differentiated, innovative, a leader, or well positioned, without describing others actually adopting or moving toward its way. NO if the movement described is the company adopting OTHERS' approaches, or the whole industry shifting for reasons unrelated to this company's example — a general trend the company is simply riding. NO if the copying or following is described chiefly as a competitive threat that is hurting the company — eroding its pricing, taking its share, or forcing defensive responses. NO if the adoption by others is only anticipated, predicted, or hoped for rather than already happening. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
AES The AES Corporation Q1 2024 2024-05-03 C+
GGR Gogoro Inc. Q1 2023 2023-05-11 D
TGT Target Corporation Q4 2022 2023-02-28 C
ORAN Orange SA Q2 2018 2018-07-26 B
USFD US Foods Holding Corp. Q1 2018 2018-05-12 C
SHOO Steven Madden, Ltd. Q1 2017 2017-04-21 C

How the model reasoned

AES · Q1 2024 → YESThe question is: Does management describe that the WAY THIS COMPANY DOES THINGS is NOW BEING ADOPTED, COPIED, OR MOVED TOWARD BY OTHERS IN ITS MARKET, so that the company's own way of doing things is ...
GGR · Q1 2023 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?
TGT · Q4 2022 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?

More from the question bank

The lull that never cameRicher on arrival: the business now flowing Fixed price, unfixed volumeSelling out of one thing at a timeCrossed from claiming to demonstratingProven engine, fuel already in the tankAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.